Result for
Tag: vaccination
May 17, 2021
The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021
On May 12th, 2021, the Advisory Committee on Immunization Practices (ACIP) made an interim recommendation for the use of the Pfizer-BioNTech vaccine among adolescents aged 12-15, following the expansion of the FDA Emergency Use Authorization age eligibility to include this age group. The ACIP considered evidence from a systematic review of published and unpublished evidence…
May 14, 2021
Plans to Vaccinate Children for COVID-19 a Survey of US Parents
[Pre-print, not peer-reviewed] A national online survey of US parents (N=2,074) conducted in March 2021 found that 49% planned to vaccinate their children for COVID-19 when available, while 26% of respondents said they would “definitely not” vaccinate their children. The most common concerns cited about vaccines were safety, effectiveness, and a perceived lack of need….
May 11, 2021
Demographic and Social Factors Associated with COVID-19 Vaccination Initiation Among Adults Aged =65 Years — United States, December 14, 2020–April 10, 2021
79% of US older adults (aged ≥65 years, n>42 million) have received at least 1 dose of a COVID-19 vaccine as of April 10, 2021. On average, counties with low vaccination rates (<50% of older adults) compared with counties with high vaccination rates (≥75% of older adults) had higher percentages of older adults who do…
May 7, 2021
Lives and Costs Saved by Expanding and Expediting COVID-19 Vaccination
A modeling study of US population dynamics and COVID-19 vaccination scenarios demonstrated that every 1% increase in coverage could avert an average of 876,800 cases, depending on the number of people already vaccinated, with the greatest gains achieved when increasing vaccine coverage in the population from 0% to 50%. Additionally, the study demonstrated that increasing…
April 30, 2021
Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination — Five U.S. Mass Vaccination Sites, April 2021
A review of data from 5 mass vaccination sites providing the Johnson & Johnson/Janssen COVID-19 vaccine (total doses=8,624) revealed 64 anxiety-related events post-vaccination, including 17 events of fainting. The most commonly-reported event was light-headedness or dizziness. 13 persons were transported to an emergency department for follow-up, and all five for whom follow-up information was available…
April 29, 2021
Impact of Vaccination on Household Transmission of SARS-COV-2 in England
[Pre-print, not peer-reviewed] Vaccinated individuals who became infected with SARS-CoV-2 had a lower rate of secondary household transmission compared to unvaccinated index individuals. Among over 550,000 residential households in the UK between January to March 2021, the overall SARS-CoV-2 secondary attack rate was 5.7% in household where the index case had received at least one…
April 28, 2021
Association of Facial Paralysis With MRNA COVID-19 Vaccines
There was no evidence for an association between facial paralysis and mRNA vaccines for SARS-CoV-2 compared to other vaccines, according to a study using World Health Organization data. Among 133,883 cases of adverse drug reactions reported with mRNA vaccines, 844 (0.6%) total facial paralysis-related events were identified, 749 of which were reported with the Pfizer-BioNTech…
Safety and Immunogenicity of One versus Two Doses of the COVID-19 Vaccine BNT162b2 for Patients with Cancer: Interim Analysis of a Prospective Observational Study
Among patients with cancer, one dose of the Pfizer-BioNTech vaccine did not elicit a strong antibody response. In a prospective observational study, the proportion of positive anti-S IgG titers measured at 21 days after vaccination was 38% among patients with solid cancers (21/56 patients), 18% among patients with hematological cancer (8/44), and 94% (32/34) among…
Vaccine Side-Effects and SARS-CoV-2 Infection after Vaccination in Users of the COVID Symptom Study App in the UK: A Prospective Observational Study
SARS-CoV-2 infection rates were lower in vaccinated persons, according to reports from the COVID Symptom Study app in the UK (n=627,383). Among Pfizer-BioNTech vaccine recipients, infections were lower by 58% 12-20 days and by 72% 45-59 days after the first dose compared to frequencies in unvaccinated users, and infection rates were also lower among Oxford-AstraZeneca…
Age-Dependent Immune Response to the Biontech/Pfizer BNT162b2 COVID-19 Vaccination
A cohort study in Germany determined that antibody titers were significantly lower in adults over age 80 (n=83) vaccinated with the Pfizer-BioNTech vaccine compared to vaccinated individuals under age 60 (n = 93) after one and two doses of the Pfizer-BioNTech vaccine. Most participants in both groups produced IgG antibodies. The magnitude of increase of…
Previous page Next page